Cyclerion Therapeutics (CYCN) Competitors $3.18 -0.12 (-3.64%) Closing price 07/15/2025 03:58 PM EasternExtended Trading$3.26 +0.07 (+2.36%) As of 07/15/2025 06:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CYCN vs. XCUR, ACRV, PEPG, STTK, ARTV, EGRX, ITRM, ELYM, KPTI, and AKTXShould you be buying Cyclerion Therapeutics stock or one of its competitors? The main competitors of Cyclerion Therapeutics include Exicure (XCUR), Acrivon Therapeutics (ACRV), PepGen (PEPG), Shattuck Labs (STTK), Artiva Biotherapeutics (ARTV), Eagle Pharmaceuticals (EGRX), Iterum Therapeutics (ITRM), Eliem Therapeutics (ELYM), Karyopharm Therapeutics (KPTI), and Akari Therapeutics (AKTX). These companies are all part of the "pharmaceutical products" industry. Cyclerion Therapeutics vs. Its Competitors Exicure Acrivon Therapeutics PepGen Shattuck Labs Artiva Biotherapeutics Eagle Pharmaceuticals Iterum Therapeutics Eliem Therapeutics Karyopharm Therapeutics Akari Therapeutics Cyclerion Therapeutics (NASDAQ:CYCN) and Exicure (NASDAQ:XCUR) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, valuation, analyst recommendations, media sentiment, profitability and earnings. Do institutionals and insiders have more ownership in CYCN or XCUR? 75.6% of Cyclerion Therapeutics shares are owned by institutional investors. Comparatively, 42.8% of Exicure shares are owned by institutional investors. 34.3% of Cyclerion Therapeutics shares are owned by company insiders. Comparatively, 8.4% of Exicure shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Is CYCN or XCUR more profitable? Cyclerion Therapeutics' return on equity of -34.02% beat Exicure's return on equity.Company Net Margins Return on Equity Return on Assets Cyclerion TherapeuticsN/A -34.02% -30.68% Exicure N/A -219.60%-82.03% Which has preferable valuation and earnings, CYCN or XCUR? Cyclerion Therapeutics has higher revenue and earnings than Exicure. Cyclerion Therapeutics is trading at a lower price-to-earnings ratio than Exicure, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCyclerion Therapeutics$2M5.10-$3.06M-$1.16-2.74Exicure$500K86.58-$9.70M-$3.82-1.79 Which has more volatility and risk, CYCN or XCUR? Cyclerion Therapeutics has a beta of 1.55, indicating that its stock price is 55% more volatile than the S&P 500. Comparatively, Exicure has a beta of 3.57, indicating that its stock price is 257% more volatile than the S&P 500. Does the media favor CYCN or XCUR? In the previous week, Cyclerion Therapeutics had 1 more articles in the media than Exicure. MarketBeat recorded 2 mentions for Cyclerion Therapeutics and 1 mentions for Exicure. Cyclerion Therapeutics' average media sentiment score of 1.87 equaled Exicure'saverage media sentiment score. Company Overall Sentiment Cyclerion Therapeutics Very Positive Exicure Very Positive SummaryCyclerion Therapeutics beats Exicure on 8 of the 11 factors compared between the two stocks. Get Cyclerion Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CYCN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CYCN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CYCN vs. The Competition Export to ExcelMetricCyclerion TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.59M$2.96B$5.61B$9.30BDividend YieldN/A2.43%4.23%4.03%P/E Ratio-2.7420.2228.5219.58Price / Sales5.10290.74426.1793.37Price / CashN/A43.1536.0257.93Price / Book0.977.568.135.54Net Income-$3.06M-$55.11M$3.24B$257.73M7 Day Performance-8.36%3.81%0.20%-0.08%1 Month Performance2.42%11.60%5.98%8.09%1 Year Performance9.66%-2.11%26.15%13.02% Cyclerion Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CYCNCyclerion Therapeutics2.5364 of 5 stars$3.18-3.6%N/A+8.9%$10.59M$2M-2.7430News CoveragePositive NewsXCURExicure1.3378 of 5 stars$6.47-4.6%N/A+1,999.3%$42.83M$500K-1.6950Positive NewsGap UpACRVAcrivon Therapeutics3.7384 of 5 stars$1.25-3.1%$17.71+1,317.1%-82.9%$40.45MN/A-0.5658Positive NewsPEPGPepGen3.0862 of 5 stars$1.11-9.0%$7.67+590.7%-92.5%$39.92MN/A-0.3530STTKShattuck Labs3.7027 of 5 stars$0.77-7.4%$7.50+871.5%-82.8%$39.92M$5.72M-0.56100News CoveragePositive NewsARTVArtiva Biotherapeutics2.8432 of 5 stars$1.58-1.9%$17.80+1,026.6%N/A$39.22M$250K0.0081EGRXEagle Pharmaceuticals2.4474 of 5 stars$3.00+3.6%N/A-37.4%$38.96M$257.55M0.00100Gap DownITRMIterum Therapeutics2.0641 of 5 stars$0.92-4.2%$9.00+874.3%-38.0%$38.56MN/A-0.9310Positive NewsGap UpELYMEliem TherapeuticsN/A$1.28+1.6%N/A-79.7%$38.08MN/A-2.429KPTIKaryopharm Therapeutics3.9673 of 5 stars$4.23-3.6%$43.20+921.3%-70.8%$37.93M$145.24M-0.32380AKTXAkari Therapeutics0.8618 of 5 stars$1.11-5.1%N/A-70.9%$37.65MN/A0.009 Related Companies and Tools Related Companies XCUR Competitors ACRV Competitors PEPG Competitors STTK Competitors ARTV Competitors EGRX Competitors ITRM Competitors ELYM Competitors KPTI Competitors AKTX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CYCN) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhy Elon is funding the “Quantum Power Grid”Elon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cyclerion Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cyclerion Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CYCN Stock Alerts